The role of periostin in the pathogenesis of retinopathy of prematurity (ROP) and the effect of 2 anti-vascular endothelial growth factors in the treatment of ROP

2016 Fiscal Year Final Research Report

• Project/Area Number: 26462654
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Ophthalmology
• Research Institution: Kindai University
• Principal Investigator: KUSAKA Shunji 近畿大学, 医学部附属病院, 教授 (60260387)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 未熟児網膜症 / 抗血管内皮増殖因子（VEGF）抗体 / Periostin / 硝子体

Outline of Final Research Achievements

Intravitreal injection of ranibizumab (IVR) was performed in 27 eyes of 14 patients with severe retinopathy of prematurity (ROP). In each eyes, improvement of vascular dilatation and tortuosity, regression of tunica vasculosa lentis, and/or whitening of fibrovascular membranes was observed. Thus, IVR seemed to be effective in reducing disease activity in all eyes. However, reactivation was seen in 7 eyes at 7.3 weeks (mean) after IVR. Suppression of serum vascular endothelial growth factor was observed only at one day, but not 1, 2, and 4 weeks after IVR, compared with that of pre-IVR.

Free Research Field

未熟児網膜症